Literature DB >> 10526099

Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion.

M Fujimura1, Y Gasche, Y Morita-Fujimura, J Massengale, M Kawase, P H Chan.   

Abstract

Blood-brain barrier (BBB) disruption is thought to play a critical role in the pathophysiology of ischemia/reperfusion. Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that can degrade all the components of the extracellular matrix when they are activated. Gelatinase A (MMP-2) and gelatinase B (MMP-9) are able to digest the endothelial basal lamina, which plays a major role in maintaining BBB impermeability. The present study examined the expression and activation of gelatinases before and after transient focal cerebral ischemia (FCI) in mice. Adult male CD1 mice were subjected to 60 min FCI and reperfusion. Zymography was performed from 1 to 23 h after reperfusion using the protein extraction method with detergent extraction and affinity-support purification. MMP-9 expression was also examined by both immunohistochemistry and Western blot analysis, and tissue inhibitors to metalloproteinase-1 was measured by reverse zymography. The BBB opening was evaluated by the Evans blue extravasation method. The 88-kDa activated MMP-9 was absent from the control specimens, while it appeared 3 h after transient ischemia by zymography. At this time point, the BBB permeability alteration was detected in the ischemic brain. Both pro-MMP-9 (96 kDa) and pro-MMP-2 (72 kDa) were seen in the control specimens, and were markedly increased after FCI. A significant induction of MMP-9 was confirmed by both immunohistochemistry and Western blot analysis. The early appearance of activated MMP-9, associated with evidence of BBB permeability alteration, suggests that activation of MMP-9 contributes to the early formation of vasogenic edema after transient FCI.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10526099     DOI: 10.1016/s0006-8993(99)01843-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  83 in total

1.  Proteomic Protease Substrate Profiling of tPA Treatment in Acute Ischemic Stroke Patients: A Step Toward Individualizing Thrombolytic Therapy at the Bedside.

Authors:  Mingming Ning; David A Sarracino; Ferdinando S Buonanno; Bryan Krastins; Sherry Chou; David McMullin; Xiaoying Wang; Mary Lopez; Eng H Lo
Journal:  Transl Stroke Res       Date:  2010-12-01       Impact factor: 6.829

Review 2.  Mechanisms of I/R-Induced Endothelium-Dependent Vasodilator Dysfunction.

Authors:  Ronald J Korthuis
Journal:  Adv Pharmacol       Date:  2017-12-08

3.  Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition.

Authors:  Zhifei Wang; Yan Leng; Li-Kai Tsai; Peter Leeds; De-Maw Chuang
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-27       Impact factor: 6.200

4.  Peak in matrix metaloproteinases-2 levels observed during recovery from olfactory nerve injury.

Authors:  Richard M Costanzo; Lisa A Perrino
Journal:  Neuroreport       Date:  2008-02-12       Impact factor: 1.837

Review 5.  Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment.

Authors:  Shadi Yaghi; Andrew Eisenberger; Joshua Z Willey
Journal:  JAMA Neurol       Date:  2014-09       Impact factor: 18.302

6.  A peptide mimetic of tyrosine phosphatase STEP as a potential therapeutic agent for treatment of cerebral ischemic stroke.

Authors:  Ranjana Poddar; Sathyanarayanan Rajagopal; Lucas Winter; Andrea M Allan; Surojit Paul
Journal:  J Cereb Blood Flow Metab       Date:  2017-12-07       Impact factor: 6.200

7.  Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation.

Authors:  Robert H Scannevin; Richard Alexander; Tara Mezzasalma Haarlander; Sharon L Burke; Monica Singer; Cuifen Huo; Yue-Mei Zhang; Diane Maguire; John Spurlino; Ingrid Deckman; Karen I Carroll; Frank Lewandowski; Eric Devine; Keli Dzordzorme; Brett Tounge; Cindy Milligan; Shariff Bayoumy; Robyn Williams; Celine Schalk-Hihi; Kristi Leonard; Paul Jackson; Matthew Todd; Lawrence C Kuo; Kenneth J Rhodes
Journal:  J Biol Chem       Date:  2017-08-31       Impact factor: 5.157

8.  Clinical predictors and management of hemorrhagic transformation.

Authors:  Raphaella E Weiser; Kevin N Sheth
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

9.  The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia.

Authors:  Candice E Junge; Taku Sugawara; Guido Mannaioni; Sudar Alagarsamy; P Jeffrey Conn; Daniel J Brat; Pak H Chan; Stephen F Traynelis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-14       Impact factor: 11.205

10.  Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.

Authors:  Stefan Lorenzl; Noel Calingasan; Lichuan Yang; David S Albers; Shuei Shugama; Jason Gregorio; H W Krell; Jason Chirichigno; Tong Joh; M Flint Beal
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.